Gilead Reports 16% Rise in Q3 2026 Base Business Sales
Gilead Sciences said HIV growth drove a 16% increase in base business sales in Q3 2026.
Related stories
Starbucks sees higher profit ahead amid turnaround progress
Starbucks expects higher profit, citing progress in its turnaround.
M impact | EARNINGS | Oct 30, 2026, 05:25 AM UTC
Sensex Edges Higher on Tech Stocks
India’s BSE Sensex edged up about 0.2% to 74,319 on Friday, extending gains from the previous session as buying in IT stocks and optimism over corporate earnings helped offset pres
H impact | EARNINGS | Oct 30, 2026, 04:53 AM UTC
BYD Electronic Reports Higher Revenue, Lower Profit for First Three Quarters
BYD Electronic reported revenue growth but a decline in net profit for the first three quarters.
M impact | EARNINGS | Oct 30, 2026, 04:49 AM UTC
Horizon Industrial Parks Revenue Rises 30% to ₹215 Crore
Horizon Industrial Parks reported a 30% year-on-year revenue increase to ₹215 crore for the quarter ended September, driven by record quarterly leasing of 2.5 million sq ft.
H impact | EARNINGS | Oct 30, 2026, 04:18 AM UTC
Nova System Reports Nine-Month Parent Recurring Profit
Parent recurring profit rose 149.3%; the company forecasts 2026 profit up 81.6%.
L impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC
LIXIL Reports Interim Operating Profit Down 44.1%
LIXIL reported consolidated interim operating profit of 63.74億円, down 44.1%. It forecasts operating profit of 375.00億円 for the fiscal year, up 32.0%.
M impact | EARNINGS | Oct 30, 2026, 04:03 AM UTC